Acute hemodynamic effects of captopril in children with a congestive or restrictive cardiomyopathy.

The acute hemodynamic effects of captopril were evaluated at cardiac catheterization in 16 children (age, 0.3-18 years) with cardiomyopathy. Twelve children had congestive cardiomyopathy, whereas four had restrictive cardiomyopathy. Hemodynamic measurements were obtained 30 and 60 minutes after the oral administration of captopril (0.5 mg/kg). Blood pressures were measured in the aorta, pulmonary artery, right atrium, and pulmonary capillary wedge position; cardiac outputs were measured by the thermodilution technique. Hemodynamic data could not be obtained after the administration of captopril in one child with congestive cardiomyopathy because of an immediate, severe hypotensive response. In 11 of 12 children with congestive cardiomyopathy, cardiac index increased by 22%, from 2.3 to 2.8 l/min/m2 (p less than 0.05), and stroke volume increased by 22%, from 23 to 28 ml/m2 (p less than 0.05). Systemic vascular resistance decreased from 32 to 21 units.m2 (p less than 0.01), but the mean aortic pressure did not change significantly. In contrast, four children with restrictive cardiomyopathy had no change in cardiac output after captopril, but there was a trend toward significant arterial hypotension (mean aortic pressure decreased from 78 to 59 mm Hg). Thus, captopril acutely reduced systemic vascular resistance and increased both cardiac output and stroke volume in children with congestive cardiomyopathy. In children with restrictive cardiomyopathy, however, captopril did not affect cardiac output, but it did decrease aortic pressure. These data indicate that captopril may benefit children with a congestive cardiomyopathy but that captopril probably should not be used in children with restrictive disease.

[1]  J. Fouron,et al.  Captopril in infants for congestive heart failure secondary to a large ventricular left-to-right shunt. , 1989, The American journal of cardiology.

[2]  N. Shaw,et al.  Captopril in heart failure secondary to a left to right shunt. , 1988, Archives of disease in childhood.

[3]  T. Graham,et al.  Guidelines for vasodilator therapy of congestive heart failure in infants and children. , 1987, American heart journal.

[4]  P. Rao,et al.  Chronic afterload reduction in infants and children with primary myocardial disease. , 1986 .

[5]  Friedman Wf,et al.  Treatment of cardiac failure in infants. , 1986 .

[6]  J. Cohn,et al.  A cooperative multicenter study of captopril in congestive heart failure: hemodynamic effects and long-term response. , 1985, American heart journal.

[7]  W. Friedman,et al.  Treatment of congestive heart failure by altering loading conditions of the heart. , 1985, The Journal of pediatrics.

[8]  P. Padfield,et al.  ANGIOTENSIN-CONVERTING ENZYME INHIBITORS: PAST, PRESENT, AND BRIGHT FUTURE , 1985, The Lancet.

[9]  B. W. East,et al.  Captopril in heart failure. A double blind controlled trial. , 1984, British heart journal.

[10]  W. Abelmann Classification and natural history of primary myocardial disease. , 1984, Progress in cardiovascular diseases.

[11]  C. Leddy,et al.  Hemodynamic effects of vasodilators and long-term response in heart failure. , 1984, Journal of the American College of Cardiology.

[12]  J. Cohn,et al.  Hemodynamic and regional blood flow response to captopril in congestive heart failure. , 1984, The American journal of medicine.

[13]  A. Rocchini,et al.  Vasodilator therapy in children: acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation. , 1984, Pediatrics.

[14]  M. Packer,et al.  Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. , 1983, Circulation.

[15]  B. Massie,et al.  Controlled Trial of Captopril in Chronic Heart Failure: A Rest and Exercise Hemodynamic Study , 1983, Circulation.

[16]  T. Graham,et al.  Congestive heart failure in childhood and adolescence: recognition and management. , 1983, American heart journal.

[17]  M. Stein,et al.  Long-term captopril therapy in severe refractory congestive heart failure. , 1982, British journal of clinical pharmacology.

[18]  A. Rocchini,et al.  Hemodynamic Effects of Hydralazine in Infants with a Large Ventricular Septal Defect , 1982, Circulation.

[19]  A. Rocchini,et al.  Hemodynamic Effects of Nitroprusside in Infants with a Large Ventricular Septal Defect , 1981, Circulation.

[20]  G. I. Nagao Use of hydralazine for intractable cardiac failure in childhood , 1981 .

[21]  S. Rubin,et al.  Vasodilator therapy for heart failure. Concepts, applications, and challenges. , 1981, JAMA.

[22]  A. Levin,et al.  Use of hydralazine for intractable cardiac failure in childhood. , 1980, The Journal of pediatrics.

[23]  B. Brundage,et al.  Immediate and Sustained Hemodynamic and Clinical Improvement in Chronic Heart Failure by an Oral Angiotensin‐converting Enzyme Inhibitor , 1980, Circulation.

[24]  T. Dillon,et al.  Vasodilator therapy for congestive heart failure. , 1980, The Journal of pediatrics.

[25]  E. Sonnenblick,et al.  Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme. , 1979, The New England journal of medicine.

[26]  D. Mason Afterload reduction and cardiac performance. Physiologic basis of systemic vasodilators as a new approach in treatment of congestive heart failure. , 1978, The American journal of medicine.

[27]  J. Cohn,et al.  Vasodilator therapy of cardiac failure (second of two parts). , 1977, The New England journal of medicine.

[28]  R. Shaddy,et al.  Short-term hemodynamic effects of captopril in infants with congestive heart failure. , 1988, American journal of diseases of children.

[29]  T. Graham,et al.  Hemodynamic effects of hydralazine in infants with idiopathic dilated cardiomyopathy and congestive heart failure. , 1987, American heart journal.

[30]  J. Cohn,et al.  Vasodilator therapy of cardiac failure: (first of two parts). , 1977, The New England journal of medicine.